|
Active substance |
Axicabtagene ciloleucel |
|
Holder |
Gilead Sciences Belgium bvba |
|
Status |
Closed |
|
Indication |
Treatment of aggressive conditions in adults with primary mediastinal B-cell lymphoma (PMBCL) affecting your lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes and other organs in your body. |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
08/03/2021 |
Yescarta
Last updated on 23/04/2024